1. Home
  2. RGS vs MAIA Comparison

RGS vs MAIA Comparison

Compare RGS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

HOLD

Current Price

$29.50

Market Cap

72.0M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.37

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
MAIA
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.0M
77.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
RGS
MAIA
Price
$29.50
$1.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.7K
495.3K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
20.24
33.33
EPS
0.89
N/A
Revenue
$210,134,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.87
N/A
Revenue Growth
3.52
N/A
52 Week Low
$18.23
$0.87
52 Week High
$31.50
$3.19

Technical Indicators

Market Signals
Indicator
RGS
MAIA
Relative Strength Index (RSI) 54.47 55.69
Support Level $25.95 $1.23
Resistance Level $28.51 $1.46
Average True Range (ATR) 1.06 0.08
MACD 0.00 0.01
Stochastic Oscillator 64.91 89.19

Price Performance

Historical Comparison
RGS
MAIA

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: